- Medicine Name: Poteligeo
- Generic Name: Mogamulizumab-kpkc
- Dosage Form & Strength: Injection: 20 mg/5 mL (4 mg/mL) solution in a single-dose vial
- Manufactured By: Kyowa Kirin, Inc.
Poteligeo is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody used for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome (two rare types of non-Hodgkin lymphoma) after at least one prior systemic therapy.
Recommended Dosage: The recommended dose of Poteligeo injection is 1 mg/kg given as an intravenous infusion over at least 60 minutes.
Administer this medication on days 1’st, 8’th, 15’th, & 22’nd of the initial 28-day cycle, then on days 1’st & 15’th of each subsequent 28-day cycle until the disease is progressive or unacceptable toxicity occurs. Administer the injection within 2 days of the scheduled dose.
In case a dose is missed, administer the very next dose as quickly as possible and resume the dosing schedule. Do not administer this medicine subcutaneously or by rapid intravenous administration.
Administer premedication with acetaminophen and diphenhydramine for the first infusion of Poteligeo.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.